Revenue was posted at Rs 763 crore and consolidated revenue was at Rs 5,826 crore
The Board of Jubilant Life Sciences has announced financial results for the quarter and year ended March31, 2015. In Q4 FY15, the consolidated revenue was at Rs 1,537 crore. The pharmaceuticals revenue was posted at Rs 763 crore, contributing 50 per cent to the overall mix. LSI revenue was at Rs 774 crore, contributing 50 per cent to the overall mix. International revenues was at Rs 1,115 crore, contributing 73 per cent to the overall mix. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) was at Rs 253 crore and margins at 16.5 per cent.
The consolidated revenue was at Rs 5,826 crore, pharmaceuticals revenue at Rs 2,682 crore, contributing 46 per cent to the overall mix, LSI revenue at Rs 3,144 crore, contributing 54 per cent to the overall mix. International revenues was at Rs 4,157 crore, contributing 71 per cent to the overall revenues. EBITDA was at Rs 732 crore with margins at 12.6 per cent.
In Q4 FY2015, income from operations of the pharmaceuticals segment was at Rs763 crore, contributing 50 per cent to the revenue mix. The segment EBITDA stood at Rs 200 crore,with EBITDA margins at 26.2 per cent. For FY2015, income from operations stood at Rs 2,682 crore,contributing 46 per cent to the overall revenue mix. The segment EBITDA stood at Rs 445 crore, with EBITDA margins at 16.6 per cent.
In Q4 FY2015, income from operations of the life science ingredients segment stood at Rs 774 crore, contributing 50 per cent to the revenue mix. The segment EBITDA stood at Rs 66 crore, with EBITDA margins at 8.5 per cent.
In FY2015, income from operations of the segment stood at Rs 3,144 crore, contributing 54 per cent to the revenue mix. The segment EBITDA stood at Rs 322 crore, with EBITDA margins at 10.2 per cent.
In Q4 FY2015,revenues from North America stood at Rs 621 crore, contributing 40 per cent to the overall revenues. Revenues from Europe and Japan stood at Rs 284 crore, contributing19 per cent to the revenue mix. Domestic revenues grew five per cent YoY and stood at Rs 422 crore, thus contributing 27 per cent to the overall mix. Revenues in ROW including China was at Rs 209 crore, thus contributing14 per cent to the overall mix.
In FY2015, revenues from North America stood at Rs. 2,191 crore, contributing 38 per cent to the revenue mix. Revenues from Europe and Japan stood at Rs 1,175 crore, contributing 20 per cent to the revenue mix. Revenues from ROW including China stood at Rs 791 crore, contributing 14 per cent to the revenue mix. Domestic revenues stood at Rs 1,669 crore, up 13 per cent YoY and contributing 29 per cent to the revenue mix.
Shyam S Bhartia, Chairman, Jubilant Life Sciences and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “Sustained strong performance in our radiopharmaceuticals business and normalisation of CMO operations supported revenue growth in the pharma segment. In life science ingredients, nutritional products and fine ingredients recorded healthy growth. Going forward, we expect the pharma segment to drive revenue growth with improvement in profitability in key businesses across both segments. We also expect the management consolidation to drive the businesses in a focussed manner to improve the operating performance. We will also continue our endeavours to strengthen the balance sheet.”
EP News Bureau – Mumbai
- Advertisement -
Comments are closed.